LGND - Ligand Pharmaceuticals Incorporated

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
116.53
+0.47 (+0.40%)
At close: 4:00PM EDT

116.53 0.00 (0.00%)
After hours: 5:17PM EDT

Stock chart is not supported by your current browser
Previous Close116.06
Open116.58
Bid116.45 x 900
Ask116.46 x 1000
Day's Range115.06 - 118.21
52 Week Range98.56 - 278.62
Volume278,472
Avg. Volume337,212
Market Cap2.284B
Beta (3Y Monthly)1.73
PE Ratio (TTM)3.53
EPS (TTM)32.97
Earnings DateJul 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-07-02
1y Target Est197.00
Trade prices are not sourced from all markets
  • Business Wire10 hours ago

    Ligand to Report Second Quarter 2019 Results on July 30th

    Ligand Pharmaceuticals Incorporated announced today plans to report second quarter 2019 financial results on July 30, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call.

  • Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expensive For A Reason? A Look At Its Intrinsic Value
    Simply Wall St.3 days ago

    Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expensive For A Reason? A Look At Its Intrinsic Value

    How far off is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) from its intrinsic value? Using the most recent...

  • Business Wire5 days ago

    Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

    Ligand Pharmaceuticals Incorporated (LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Based on top line data, the trial achieved the primary endpoint demonstrating pharmacokinetic bioequivalence between CE-Iohexol injection and a reference Iohexol injection (OMNIPAQUE™) after intravenous (IV) administration in healthy adults.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.

    Ligand Pharmaceuticals Inc NASDAQ NMS:LGNDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for LGND with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting LGND. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding LGND totaled $64.13 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
    PR Newswire7 days ago

    Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation

    SQ Innovation will use Ligand's Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure. The smaller delivery volume enables use of established drug container and device technology developed for insulin and other biologics, resulting in faster development and reduced cost. SQ Innovation to use advanced 3 mL drug delivery platform by Sensile Medical AG, a Gerresheimer company, for the novel treatment.

  • Business Wire14 days ago

    ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics

    Ligand Pharmaceuticals Incorporated (LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy. With this launch, ZULRESSO is the 11th FDA-approved drug to use Ligand’s patented Captisol technology. ZULRESSO is administered via continuous intravenous (IV) infusion for 2.5 days under the supervision of healthcare providers in sites of care certified under the ZULRESSO Risk Evaluation and Mitigation Strategy (REMS) program.

  • What does Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Balance Sheet Tell Us About Its Future?
    Simply Wall St.25 days ago

    What does Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Balance Sheet Tell Us About Its Future?

    Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Ligand...

  • Ligand Inks Oncology Drug Discovery Deal With PhoreMost
    Zackslast month

    Ligand Inks Oncology Drug Discovery Deal With PhoreMost

    Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.

  • Business Wirelast month

    Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target

    Ligand Pharmaceuticals Incorporated (LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target. PhoreMost has identified and validated the target using its next-generation SITESEEKER® phenotypic screening technology. Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors against the target, to help rapidly progress compounds through hit-to-lead and lead optimization stages.

  • Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy?
    Insider Monkeylast month

    Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy?

    How do we determine whether Ligand Pharmaceuticals Inc. (NASDAQ:LGND) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]

  • Should You Worry About Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Salary Level?
    Simply Wall St.last month

    Should You Worry About Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Salary Level?

    John Higgins became the CEO of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) in 2007. First, this article will...

  • GuruFocus.comlast month

    Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $108,200 of Shares

    CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins bought 1,000 shares of LGND on 05/31/2019 at an average price of $108.2 a share.

  • Ligand Grants Preclinical Candidate Rights to UK-based Firm
    Zacks2 months ago

    Ligand Grants Preclinical Candidate Rights to UK-based Firm

    Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

  • Business Wire2 months ago

    Ligand Licenses VER250840 to Cumulus Oncology

    Ligand Pharmaceuticals Incorporated (LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP). Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and tiered royalties in the mid-to-high single digit range, depending on revenue. In addition, Ligand is eligible to receive an additional fee, payable in cash or Cumulus equity, upon Cumulus achieving specified financing-related events.

  • GuruFocus.com2 months ago

    Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $283,750 of Shares

    CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins bought 2,500 shares of LGND on 05/14/2019 at an average price of $113.5 a share.

  • A Closer Look At Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Impressive ROE
    Simply Wall St.2 months ago

    A Closer Look At Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Impressive ROE

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates
    Zacks2 months ago

    AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

    AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

  • Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View
    Zacks2 months ago

    Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View

    Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of LGND earnings conference call or presentation 2-May-19 8:30pm GMT

    Q1 2019 Ligand Pharmaceuticals Inc Earnings Call

  • Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss
    Zacks2 months ago

    Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss

    Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.

  • Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1
    Zacks2 months ago

    Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1

    Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.